Nav: Home

The IASLC Atlas of PD-L1 Immunohistochemistry (IHC) Testing in Lung Cancer released

May 03, 2017

Media Contact: Becky Bunn, MSc Public Relations Manager | 720-325-2946

The IASLC Atlas of PD-L1 Immunohistochemistry (IHC) Testing in Lung Cancer Released Publication the First to Collectively Discuss All Five PD-L1 IHC Assays

DENVER - Despite very encouraging progress in the development and use of immunotherapy for patients with non-small cell lung cancer, much confusion remains regarding patient selection for each therapy. There is no clear understanding among physicians, health care personnel or patients regarding which assay to use for programmed cell death ligand-1 (PD-L1) testing or whether the various assays are interchangeable because each assay was co-developed with a therapy. No publication to date has collectively evaluated all five of the currently available assays.

"This complex biomarker scenario--the likes of which we have not faced before in lung cancer diagnostics--poses many challenges for pathologists, oncologists and patients," said Dr. Fred R. Hirsch, MD, PhD, Professor of Medicine and Pathology at the University of Colorado Cancer Center and School of Medicine, and CEO of the International Association for the Study of Lung Cancer (IASLC). "At present, although PD-L1 protein expression, as detected by IHC testing, is widely used as a predictive biomarker assay for anti-PD-1/ PD-L1 therapies, more information is needed regarding interpretation, assay usage for PD-L1 testing and potential interchangeability."

As the leading global organization for lung cancer research, the IASLC recognized the importance and timeliness of this topic and its unique position to educate stakeholders around the world about PD-L1 testing. The IASLC convened an expert panel of authors to present current information about the emerging PD-L1 IHC assays, as well as to highlight both areas of clarity and debate. The authors evaluated the changing landscape of laboratory testing in general and then focused on the specifics of each assay and on the current controversies regarding PD-L1 expression testing in lung cancer.

Although this Atlas primarily aims to be a guide or resource for physicians and others involved in lung cancer diagnosis and treatment, it is hoped that this text may also eventually give patients a more comprehensive understanding of their current biomarker treatment options.

"Ultimately, we hope that through the creation of this Atlas, patients with lung cancer will receive the most contemporary and well-suited treatment options based on up-to-date evidence, and will feel more confident and knowledgeable regarding their therapy," adds Hirsch.
The IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer will be released this Friday, May 5th at the European Lung Cancer Conference (ELCC). Hard copies will be available at upcoming IASLC meetings. The publication can be downloaded here in English currently and in several other languages in the coming year.

About the IASLC

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer. Founded in 1974, the association's membership includes more than 5,500 lung cancer specialists in over 100 countries. Visit for more information.

International Association for the Study of Lung Cancer

Related Lung Cancer Articles:

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.
Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.
Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.
Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.
Better equipped in the fight against lung cancer
Lung cancer is the third most common type of cancer in Germany and the disease affects both men and women.
New liquid biopsy-based cancer model reveals data on deadly lung cancer
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes.
Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient
Doctors in France have found the first evidence that a cancer drug may be able to eradicate HIV-infected cells in humans.
More Lung Cancer News and Lung Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Warped Reality
False information on the internet makes it harder and harder to know what's true, and the consequences have been devastating. This hour, TED speakers explore ideas around technology and deception. Guests include law professor Danielle Citron, journalist Andrew Marantz, and computer scientist Joy Buolamwini.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at     You can read The Transition Integrity Project's report here.